{"entity":{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","aka":["CU Cancer Center"],"tldr":"The University of Colorado Cancer Center serves the Rocky Mountain states; its thoracic oncology group defined how ALK, ROS1 and NTRK fusion-driven lung cancers behave and helped bring crizotinib, entrectinib and larotrectinib to patients, and it holds a lung cancer SPORE grant.","summary":"NCI-designated since 1988 and comprehensive since 1997, the CU Cancer Center on the Anschutz Medical Campus serves Colorado and the surrounding mountain states. Its thoracic oncology group, built by Paul Bunn and Fred Hirsch and continued by Ross Camidge and Robert Doebele, defined the clinical behaviour of ALK, ROS1 and NTRK fusion-driven lung cancers and helped bring crizotinib, entrectinib and larotrectinib to patients. The centre holds a lung cancer SPORE, and its partners include UCHealth and Children's Hospital Colorado.","asOf":"2026-09-09","links":[{"label":"University of Colorado Cancer Center","url":"https://medschool.cuanschutz.edu/colorado-cancer-center"},{"label":"Clinical trials","url":"https://medschool.cuanschutz.edu/colorado-cancer-center/clinical-trials"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["alk","ros1","ntrk"],"drugs":["crizotinib","entrectinib","larotrectinib","lorlatinib"],"companies":[],"institutions":[],"pathways":[],"terms":["gene-fusion","oncogene-addiction"],"trials":[],"people":["richard-schulick","ross-camidge","sapna-patel"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Aurora, CO","country":"US","lat":39.745,"lng":-104.838,"institutionType":"cancer-center","website":"https://medschool.cuanschutz.edu/colorado-cancer-center","nci":"comprehensive","university":"University of Colorado Anschutz Medical Campus","programs":["Oncogene-driven lung cancer","Lung cancer SPORE","Paediatric oncology (Children's Colorado)"]},"route":"/institutions/colorado-cancer-center/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/"},{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/"}],"drug":[{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"},{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/"},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/"}],"term":[{"id":"gene-fusion","kind":"term","name":"Gene fusion","route":"/terms/gene-fusion/"},{"id":"oncogene-addiction","kind":"term","name":"Oncogene addiction","route":"/terms/oncogene-addiction/"}],"person":[{"id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/"},{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","route":"/people/ross-camidge/"},{"id":"richard-schulick","kind":"person","name":"Richard Schulick","route":"/people/richard-schulick/"},{"id":"sapna-patel","kind":"person","name":"Sapna P. Patel","route":"/people/sapna-patel/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}]}}